FDA approves Regeneron antibody drug as first Ebola virus treatment

Bio Pharma Dive

Research for the drug, now cleared as Inmazeb, helped Regeneron jumpstart its fast development of an antibody therapy for COVID-19

Regeneron enlists Roche to boost production of COVID-19 antibody drug

Bio Pharma Dive

Together, the companies expect to make three and a half times as many doses of Regeneron's antibody drug than the U.S. biotech could on its own

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron follows Lilly in asking for emergency approval of COVID-19 antibody drug

Bio Pharma Dive

The two antibody treatments are now being reviewed by the FDA, although limited supply could mean their impact won't be felt for months, even if they are cleared for use

Merck pays Seattle Genetics $1.7B as antibody cancer drugs continue comeback

Bio Pharma Dive

Merck's deal for Seattle Genetics' antibody-drug conjugate comes as Gilead agreed to acquire rival developer Immunomedics in the biotech industry's largest buyout of 2020

Regeneron’s Antibody Drug Becomes First Approved Treatment for Ebola

XTalks

Inmazeb is a combination of three different antiviral monoclonal antibodies. The three monoclonal antibodies contained in Inmazeb are of similar structure; however, they bind to different, non-overlapping epitopes simultaneously on a glycoprotein found on the surface of the Ebola virus.

Lilly, with new data, seeks emergency clearance for COVID-19 antibody drug

Bio Pharma Dive

The pharma is the first to seek emergency approval for this kind of treatment, and may quickly follow up with a second request after reporting promising data for a two-drug combination

Fujifilm to help Lilly make COVID-19 antibody drug

Bio Pharma Dive

Lilly has asked the FDA for emergency clearance of the therapy, although a study safety review and an unrelated manufacturing inspection could complicate the request

Companies Press Ahead with COVID-19 Antibody Therapies

BioSpace

Although the world is eagerly awaiting news of an effective and safe vaccine against COVID-19, several companies are moving ahead testing therapeutic antibodies against the disease

U.S. Government Inks Antibody Cocktail Deal with AstraZeneca

BioSpace

government program to advance COVID-19 vaccines and therapeutics, for a monoclonal antibody cocktail AstraZeneca signed a deal with Operation Warp Speed, the U.S.

UPMC Researchers Isolate Tiny Antibody That Neutralizes SARS-CoV-2 Virus

BioSpace

The researchers used this antibody, which is 10-times smaller than a full-sized antibody and the smallest isolated biological molecule to date, to develop a potential therapeutic and prophylactic agent against the virus termed “Ab8

Roche Launches New COVID-19 Antibody Test to Support Vaccine Testing

BioSpace

Roche launched its Elecsys Anti-SARS-CoV-2 S antibody test for markets that accept the CE Mark

Lilly offers first evidence that its antibody drug may help treat COVID-19

Bio Pharma Dive

The results, from a mid-stage study of Lilly's drug, suggest treatment helped lower virus levels, but the degree to which patients benefited remains unclear

Regeneron says antibody drug may speed recovery of patients with mild COVID-19

Bio Pharma Dive

Preliminary study data suggest the treatment could help people whose bodies aren't already fighting off infection, a finding the biotech is discussing with regulators

Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools

BioTech 365

CHICAGO & MUNICH–(BUSINESS WIRE)–#Antibodies–Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.

Oncotarget: A novel format for recombinant antibody-interleukin-2 fusion proteins

Scienmag

and Alessandra Villa – alessandra.villa@philogen.com Oncotarget recently published “A novel format for recombinant antibody-interleukin-2 fusion proteins […].

Eli Lilly’s Antibody Therapy Against COVID-19 Reduced Hospitalization Rates

BioSpace

Eli Lilly and Company announced interim proof-of-concept data from its BLAZE-1 Phase II clinical trial of LY-COV555, its neutralizing antibody therapy for COVID-19

Lilly to test COVID-19 antibody drug in unorthodox nursing home study

Bio Pharma Dive

Seeking fast answers in a pandemic, Lilly will use mobile RVs to set up infusion clinics at assisted living facilities, which have become COVID-19 hot spots

Nurses 248

The Race for a Super-Antibody Against the Coronavirus

NY Times

A network of scientists is chasing the pandemic’s holy grail: an antibody that protects against not just the virus, but also related pathogens that may threaten humans

Vir, GSK push coronavirus antibody drug straight into mid-stage tests

Bio Pharma Dive

The two companies, chasing rival treatments from Eli Lilly, Regeneron and more, aim to produce their first study results by the end of the year

Regeneron’s antibody cocktail active against coronavirus, cuts symptoms

Pharma Phorum

Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. REGN-COV2 is a combination of two monoclonal antibodies and was designed to block infectivity of SARS-CoV-2 , the virus that causes COVID-19.

In recovering COVID-19 patients, antibodies fade quickly

Scienmag

The blood of recovered patients contains antibodies that act against the coronavirus. Washington, DC – October 16, 2020 – In the absence of approved, effective treatments for COVID-19, some hospitals have been treating patients with severe COVID symptoms with blood plasma from recovering patients. While plasma hasn’t yet shown a benefit in randomized trials, some […]. Biology Microbiology Public Health Virology

Coronavirus: Monoclonal antibodies to begin UK trial

The Pharma Data

Illustration of antibodies attacking the coronavirus. A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. What are monoclonal antibodies? Antibodies could be described as the “warriors” of the immune system. Image copyright.

Model-based Strategy to Guide the Choice of Clinical Doses for ADC

Pharma R&D Today

Enter antibody-drug conjugates (ADCs). They have developed novel modelling and simulation-based tools to guide the choice of the most promising safe and efficacious dosing regimen of an innovative antibody drug conjugate.

IONTAS and FairJourney Biologics discover COVID-19 neutralizing antibodies

BioPharma Reporter

Two leading clinical research organizations (CROs) say they have identified neutralizing antibodies with great potential for monoclonal antibody treatment.

Antibodies protect against wide range of influenza B virus strains

Scienmag

Findings point the way to developing a broad-spectrum flu drug Credit: Yanan Dai Researchers have identified two antibodies that protect mice against lethal infections of influenza B virus, report scientists at Washington University School of Medicine in St.

Lilly’s antibody therapy cuts hospitalisation rates in COVID-19

Pharma Phorum

Eli Lilly has followed up supportive data from its Olumiant in COVID-19 with results of a study showing its antibody treatment could help prevent hospitalisation from the disease. The post Lilly’s antibody therapy cuts hospitalisation rates in COVID-19 appeared first on.

Regeneron targets September data drop from COVID-19 antibody trial

BioPharma Reporter

Regeneron Pharmaceuticals aims to post initial virology and biomarker data from clinical trials of its COVID-19 antibody cocktail next month. Bio Developments

Flexible targets help immune system make finely-tuned antibodies

Scienmag

An in-depth Garvan study of how the immune system generates effective antibodies provides new insights for vaccine design.

#news #biotech Chinese COVID-19 vaccine trial reports falling antibody titers

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Chinese COVID-19 vaccine trial reports falling antibody titers.Chinese COVID-19 vaccine trial reports falling antibody titers ntaylor Wed, 10/07/2020 – 08:57 from FierceBiotech: Biotech [link].

AstraZeneca's coronavirus antibody drug cocktail begins human tests as rivals slip

Bio Pharma Dive

The British pharma has started a Phase 1 trial amidst reports that competing programs from Regeneron and Eli Lilly haven't met their projected timelines

UCSF Researchers Develop Synthetic Llama Antibodies Against COVID-19

BioSpace

They are approximately 25% of the size of human antibodies and from other animals, and they appear to be the most potent anti-coronavirus compound that has been tested in the laboratory so far

Promising Early Data Prompts Eli Lilly to Seek EUA for COVID-19 Antibody Treatment

BioSpace

Eli Lilly is seeking Emergency Use Authorization for its antibody therapy, LY-CoV555, for the treatment of high-risk patients with recently diagnosed mild-to-moderate coronavirus disease 2019 (COVID-19

Coronavirus antibodies tests 'put public at risk'

The Pharma Data

Poor regulation of antibodies tests – that could indicate if someone has had coronavirus – could be putting the public at risk, doctors have warned. It is still not known whether having antibodies will protect people from a second infection. Image copyright. Getty Images.

bioLytical Laboratories Announces Launch of INSTI® 1-Minute COVID-19 Antibody Test

BioTech 365

INSTI® COVID-19 Antibody Test is bioLytical’s new one-minute test, detecting antibodies to SARS-CoV-2 with high accuracy. bioLytical has received CE Mark and approval to sell the test across Europe. bioLytical announced today that test kits are now available in Europe. … Continue reading → GlobeNewswire

Patients taking long-term opioids produce antibodies against the drugs

Scienmag

— University of Wisconsin-Madison scientists have discovered that a majority of back-pain patients they tested who were taking opioid painkillers produced anti-opioid antibodies. These antibodies may contribute to some of the negative side effects of long-term opioid use. Existing antibodies may also limit the benefit a patient receives from an anti-opioid vaccine, the […]. MADISON, Wis.

CR UK, AZ researchers pioneer new antibody maturation technique

The Pharma Data

The technique has been used to generate a high-affinity antibody against Arginase 2, an enzyme implicated in major human diseases.

Roche, Regeneron ally to triple supply of COVID-19 antibody cocktail

BioPharma Reporter

Roche agrees to distribute Regeneronâs COVID-19 antibody combination outside the US, more than tripling manufacturing capacity. Downstream Processing

Vir Bio and GSK Join the Race for a COVID-19 Monoclonal Antibody Therapy

BioSpace

Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19

Patients with recently discovered antibodies have more severe myasthenia gravis

Scienmag

Global Monoclonal Antibodies Market to Surpass US$ 368.8 Billion by 2027, Says Coherent Market Insights (CMI)

BioTech 365

SEATTLE–(BUSINESS WIRE)–#Antibodies–According to Coherent Market Insights, the global monoclonal antibodies market is estimated to be valued at US$ 143.5